What Is the Best Injection for Weight Loss?
The best injection for weight loss depends on the individual. In SURMOUNT-1, participants in the highest-dose tirzepatide group lost an average of 20.9% of their body weight at 72 weeks. In STEP 1, participants in the semaglutide group lost an average of 14.9% at 68 weeks. The figures come from separate trials. A licensed provider can help decide which treatment is appropriate.
More on Comparisons
2025 GLP-1 Rankings for Weight Loss
Based on the latest clinical trial data, real-world evidence, and meta-analyses, here are our rankings for GLP-1 medications for weight loss in 2025:
Tirzepatide (Mounjaro/Zepbound)
The dual GIP/GLP-1 agonist leads all medications for weight loss efficacy. Learn more in our complete tirzepatide guide.
Semaglutide (Wegovy/Ozempic)
The most widely prescribed and studied GLP-1 for weight loss. Excellent efficacy with the longest safety record. See our semaglutide guide.
Liraglutide (Saxenda)
The original GLP-1 approved for obesity. Less effective than newer options but well-studied with a strong safety profile.
Head-to-Head Comparison
| Feature | Tirzepatide | Semaglutide | Liraglutide |
|---|---|---|---|
| Avg Weight Loss (pivotal trial) | ~20.9% (SURMOUNT-1, 72 wk) | ~14.9% (STEP 1, 68 wk) | 5-8% |
| Dosing Frequency | Weekly | Weekly | Daily |
| A1c Reduction | 2.0-2.4% | 1.5-1.8% | 1.0-1.2% |
| Brand Cost/Month | $1,000-1,300 | $900-1,100 | $900-1,000 |
| Compounded Available | Limited | Yes | No |
| GI Side Effects | Moderate | Moderate | Moderate-High |
| CV Outcomes Data | SURPASS-CVOT (2025) | Strong (SELECT) | Neutral (LEADER) |
For detailed cost comparisons, see our complete GLP-1 cost guide.
Our Comparison Methodology
Ranking GLP-1 medications requires looking beyond a single metric. Weight loss percentage grabs headlines, but the medication that produces the most average weight loss in a clinical trial is not automatically the best choice for every patient. Our 2025 rankings integrate several data sources and evaluation criteria to give a more complete picture of how these medications perform across different dimensions.
We began by reviewing the pivotal Phase 3 trials for each medication, including the STEP program for semaglutide, SURMOUNT for tirzepatide, and SCALE for liraglutide. These trials provide the gold-standard evidence for efficacy and safety, but they are conducted in controlled environments with selected patient populations. To complement trial data, we examined real-world evidence from electronic health record analyses, pharmacy claims databases, and published observational cohorts. Real-world data often shows more modest weight loss than clinical trials, but it reflects how medications perform outside of research settings where adherence, dose titration, and follow-up are less tightly managed.
Beyond raw efficacy, our methodology weights several additional factors. Tolerability matters because a medication that produces excellent weight loss but causes intolerable side effects leading to discontinuation is not practically effective. We considered discontinuation rates, the severity and duration of gastrointestinal side effects, and how quickly patients can titrate to therapeutic doses. Cardiovascular safety data plays a role as well, particularly the SELECT trial results for semaglutide, which demonstrated a 20% reduction in major adverse cardiovascular events. Tirzepatide's dedicated cardiovascular outcome trial, SURPASS-CVOT, reported results in 2025, meeting its primary endpoint against the active comparator dulaglutide in patients with type 2 diabetes; placebo-controlled outcome data in patients without diabetes, like semaglutide's SELECT trial, remains a distinguishing factor.
Accessibility and cost also factor into our rankings. A medication that most patients cannot afford or access provides limited real-world value regardless of its clinical trial performance. We evaluated insurance coverage rates, out-of-pocket costs, manufacturer savings program availability, and whether compounded alternatives exist. Finally, we considered the breadth of evidence, including how long a medication has been on the market, the volume of published research, the diversity of populations studied, and the availability of long-term follow-up data. Medications with deeper evidence bases provide greater confidence in their safety and efficacy profiles.
How Trial Results Inform Treatment
Trial results describe outcomes in the groups studied. A licensed provider decides whether treatment is appropriate and which medication to prescribe.
Insurance, Cost, and Affordability Factors
The financial landscape for GLP-1 medications in 2025 remains one of the biggest barriers to treatment. List prices for brand-name medications range from approximately $900 to $1,350 per month, but the actual cost a patient pays varies enormously depending on their insurance status, plan design, and ability to access savings programs. Understanding these financial dynamics is essential for making a practical medication choice rather than a purely clinical one.
Commercial insurance coverage for GLP-1 weight loss medications has expanded significantly since the publication of the SELECT cardiovascular outcomes data. Many large employers and commercial plans now cover Wegovy or Zepbound, though often with prior authorization requirements, step therapy protocols, or BMI thresholds. Patients should review their specific formulary and contact their plan to understand what criteria must be met before coverage is approved. Prior authorization typically requires documentation of BMI, comorbidities, and sometimes evidence of prior weight loss attempts through diet and exercise.
Medicare Part D did not cover anti-obesity medications as of early 2025, leaving millions of older Americans without coverage. The Treat and Reduce Obesity Act would change this exclusion, but as of early 2025 it had not been enacted. Medicaid coverage varies by state, with some state programs covering GLP-1 medications for weight loss and others maintaining exclusions. Patients on government insurance should check their specific plan and consider manufacturer patient assistance programs if they meet income eligibility requirements.
Before paying for treatment, check the full charge, billing term, and what the plan includes. Ask your provider or insurer about separate charges for visits, lab work, or supplies.
Emerging and Pipeline Options to Watch
The GLP-1 medication landscape is evolving rapidly, with several next-generation therapies in late-stage clinical development that may reshape the rankings in 2026 and beyond. Understanding what is in the pipeline helps patients and providers plan ahead and set appropriate expectations about future options that may offer improved efficacy, convenience, or affordability.
Oral formulations represent a major area of development. Oral semaglutide for weight loss at higher doses (50 mg daily) has shown promising results in the OASIS trial program, with weight loss approaching that of injectable semaglutide. If these oral options achieve comparable efficacy to injectables, they could dramatically expand access by eliminating the injection barrier that deters some patients from starting treatment. Orforglipron, a small-molecule oral GLP-1 agonist from Eli Lilly, represents yet another approach. Unlike oral semaglutide, which is a peptide requiring special formulation to survive the digestive tract, orforglipron is a non-peptide molecule that may be easier to manufacture at scale, potentially lowering costs. In the Phase 3 ATTAIN-1 trial, reported in 2025, orforglipron produced approximately 12.4% average weight loss at 72 weeks at its highest dose.
CagriSema, developed by Novo Nordisk, combines semaglutide with cagrilintide, an amylin analog. Early data suggests this combination produces greater weight loss than semaglutide alone, potentially narrowing or closing the efficacy gap between semaglutide and tirzepatide. Amylin works through complementary appetite suppression pathways, and the combination approach may provide a more comprehensive metabolic effect. In the Phase 3 REDEFINE-1 trial, CagriSema produced approximately 22.7% average weight loss at 68 weeks, confirming greater efficacy than semaglutide alone and clarifying where CagriSema fits relative to existing options.
Choosing the Right GLP-1 for You
A licensed provider determines eligibility and whether a treatment is appropriate. Bring questions about side effects, cost, and follow-up to that discussion.
Next-Generation Options: 2025 Trial Readouts
Semaglutide 7.2 mg
Investigational higher dose produced approximately 20.7% average weight loss at 72 weeks in the STEP UP trial.
Orforglipron
Daily oral GLP-1 that produced approximately 12.4% average weight loss at 72 weeks in ATTAIN-1. Potential cost advantages over injectables.
CagriSema
Semaglutide plus cagrilintide produced approximately 22.7% average weight loss at 68 weeks in REDEFINE-1.
Frequently Asked Questions
What is the best injection for weight loss?
The best injection for weight loss depends on the individual. In SURMOUNT-1, participants in the highest-dose tirzepatide group lost an average of 20.9% of their body weight at 72 weeks. In STEP 1, participants in the semaglutide group lost an average of 14.9% at 68 weeks. The figures come from separate trials. A licensed provider can help decide which treatment is appropriate.
Is tirzepatide better than semaglutide for weight loss?
In their pivotal trials, tirzepatide averaged approximately 20.9% weight loss at 72 weeks (SURMOUNT-1) versus approximately 14.9% at 68 weeks for semaglutide 2.4 mg (STEP 1). However, individual responses vary, and some patients respond better to semaglutide. Cost, availability, and side effect tolerance also factor into the best choice.
What costs should I compare before choosing a GLP-1 plan?
Check the full charge, the billing term, and whether provider visits, lab work, and supplies are included. See our cost guide for Trimi’s current plan details.
What new GLP-1 trial results were reported in 2025?
In 2025, orforglipron, a daily oral GLP-1, produced approximately 12.4% average weight loss at 72 weeks in the ATTAIN-1 trial; CagriSema (semaglutide plus cagrilintide) produced approximately 22.7% at 68 weeks in REDEFINE-1; and investigational semaglutide 7.2 mg produced approximately 20.7% at 72 weeks in STEP UP. Orforglipron was subsequently FDA-approved as Foundayo on April 1, 2026. Trimi does not offer it. Individual results vary.
Find Your Best GLP-1 Match
Our medical team will evaluate your health profile, goals, and preferences to recommend the optimal medication.
Get Personalized RecommendationSources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.